ESSA PHARMA INC (EPIX) Stock Analyst Earnings Estimates
NASDAQ:EPIX - Nasdaq - CA29668H7085 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 682.97% | N/A 88.89% | N/A 354.69% | N/A 27.13% | N/A 15.48% | N/A 9.72% | ||||||||||||
| EBITDA YoY % growth | -2.92M | -15.8M -441.10% | -18.63M -17.91% | -16.01M 14.06% | -11M 31.29% | N/A -19.62% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -2.94M | -15.84M -438.78% | -18.7M -18.06% | -16.06M 14.12% | -11.03M 31.32% | -12.15M -10.15% | -23.93M -96.95% | -37.16M -55.29% | -36.97M 0.51% | -32.141M 13.06% | -34.421M -7.09% | N/A 23.98% | N/A 33.47% | N/A 188.55% | N/A 458.04% | N/A 415.55% | N/A 27.97% | N/A 15.84% | N/A 9.90% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | -1.51 43.06% | -1.04 31.13% | -0.97 6.73% | -0.80 17.53% | -0.60 25.00% | -0.64 -6.67% | N/A 23.10% | N/A 34.20% | N/A 218.11% | N/A 355.25% | N/A 404.53% | N/A 25.61% | N/A 13.93% | N/A 8.10% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 38.80% | -0.09 45.81% | -0.09 38.07% | -0.04 78.53% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.355M 48.97% | -4.08M 52.77% | -4.08M 46.98% | -2.04M 78.94% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.19 -35.71% | -0.18 | -0.01 | -3.49% |
| Q4 2024 Q2Q % growth | -0.14 -16.67% | -0.20 | 0.06 | 29.61% |
| Q3 2024 Q2Q % growth | -0.16 5.88% | -0.25 | 0.09 | 36.23% |
| Q2 2024 Q2Q % growth | -0.20 -25.00% | -0.19 | -0.01 | -4.30% |
| Q1 2024 Q2Q % growth | -0.14 6.67% | -0.18 | 0.04 | 20.43% |
| Q4 2023 Q2Q % growth | -0.12 14.29% | -0.21 | 0.09 | 43.98% |
| Q3 2023 Q2Q % growth | -0.17 15.00% | -0.20 | 0.03 | 14.53% |
| Q2 2023 Q2Q % growth | -0.16 36.00% | -0.21 | 0.05 | 23.48% |
| Q1 2023 Q2Q % growth | -0.15 28.57% | -0.24 | 0.09 | 37.42% |
| Q4 2022 Q2Q % growth | -0.14 30.00% | -0.28 | 0.14 | 50.09% |
| Q3 2022 Q2Q % growth | -0.20 4.76% | -0.28 | 0.08 | 27.38% |
| Q2 2022 Q2Q % growth | -0.25 30.56% | -0.26 | 0.01 | 2.93% |
| Q1 2022 Q2Q % growth | -0.21 -5.00% | -0.23 | 0.02 | 10.49% |
| Q4 2021 Q2Q % growth | -0.20 -53.85% | -0.24 | 0.04 | 15.67% |
| Q3 2021 Q2Q % growth | -0.21 12.50% | -0.27 | 0.06 | 21.57% |
| Q2 2021 Q2Q % growth | -0.36 20.00% | -0.22 | -0.14 | -64.93% |
| Q1 2021 Q2Q % growth | -0.20 9.09% | -0.17 | -0.03 | -15.34% |
| Q4 2020 Q2Q % growth | -0.13 43.48% | -0.20 | 0.07 | 34.64% |
| Q3 2020 Q2Q % growth | -0.24 53.85% | -0.30 | 0.06 | 19.79% |
| Q2 2020 Q2Q % growth | -0.45 16.67% | -0.22 | -0.23 | -100.53% |
| Q1 2020 Q2Q % growth | -0.22 59.26% | -0.18 | -0.04 | -23.25% |
| Q4 2019 Q2Q % growth | -0.23 | -0.17 | -0.06 | -32.64% |
| Q3 2019 Q2Q % growth | -0.52 | -0.55 | 0.03 | 5.59% |
| Q2 2019 Q2Q % growth | -0.54 | -0.45 | -0.09 | -20.32% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -4.35% | 75.51% | 4.27% | 4.27% |
| Revenue | N/A | N/A | N/A | N/A |